<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="71a854a1-d9af-4f37-a43c-ba3cafafc2c5"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>LOMAIRA</title>
   <effectiveTime value="20250528"/>
   <setId root="329da53b-6f26-4590-be0d-2f20b0ab7b84"/>
   <versionNumber value="6"/>
   <author>
      <assignedEntity>
         <representedOrganization>
            <id extension="830016429" root="1.3.6.1.4.1.519.1"/>
            <name>A-S Medication Solutions</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="830016429" root="1.3.6.1.4.1.519.1"/>
                        <name>A-S Medication Solutions</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" displayName="RELABEL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50090-7560" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="29dbf682-7ea8-4545-844b-bf6c8b3079e4"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20231219"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50090-7560" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>LOMAIRA</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Phentermine Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="10702-001" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BLUE 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="8" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0K2I505OTV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENTERMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="C045TQL4WP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHENTERMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="50090-7560-0" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250527"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA203495" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20160912"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText>Speckles</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">K;1</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="3" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48340" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="FREEFORM" xsi:type="CE">
                              <originalText>Butterfly Shape</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48677" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CIV"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Lc75a43de-7e20-4a8a-91c4-364e4c5c2dff">
               <id root="81e9d242-6c56-4765-9eab-76a10a86bfda"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Phentermine hydrochloride is a sympathomimetic amine anorectic. Its chemical name is α,α,-dimethylphenethylamine hydrochloride. The structural formula is as follows:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L942f9793-a640-466b-9959-3806eae3e9d5"/>
                  </paragraph>
                  <paragraph>Phentermine hydrochloride is a white, odorless, hygroscopic, crystalline powder which is soluble in water and lower alcohols, slightly soluble in chloroform and insoluble in ether.</paragraph>
                  <paragraph>LOMAIRA™ tablet is available as an oral tablet containing 8 mg of phentermine hydrochloride (equivalent to 6.4 mg of phentermine base). Each LOMAIRA™ tablet also contains the following inactive ingredients: Corn Starch, Magnesium Stearate, NF, Microcrystalline Cellulose 102, NF, Stearic Acid, NF, FD&amp;C Blue #1 and Sucrose.</paragraph>
               </text>
               <effectiveTime value="20231219"/>
               <component>
                  <observationMedia ID="L942f9793-a640-466b-9959-3806eae3e9d5">
                     <text>chemical-structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="chemical-structure-figure-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="b60fdbe9-14c5-4f42-8550-24170e2d8000">
               <id root="e6b79e8c-27fd-4186-b9b9-fe311323bce2"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20160823"/>
               <component>
                  <section ID="b3b4277f-e80a-45f0-84e1-b78c42d10369">
                     <id root="17f753f6-7c63-49ba-bd72-cb1b65e48489"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Phentermine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and dll-amphetamine). Drugs of this class used in obesity are commonly known as “anorectics” or “anorexigenics.” It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.</paragraph>
                     </text>
                     <effectiveTime value="20160823"/>
                  </section>
               </component>
               <component>
                  <section ID="bd712c19-30a5-4acf-b4ad-723e6f0f14e2">
                     <id root="cea2ce7e-8ea8-4c6e-a74b-a7462c505650"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>Typical actions of amphetamines include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="be9d2175-4dce-4d10-99e0-fa4fe3acd4ec">
                     <id root="7b822d2f-2e69-4e10-a45c-e49ae4ddae12"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Impairment</content>
                        </paragraph>
                        <paragraph>Phentermine was not studied in patients with renal impairment. The literature reported cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions is 62%-85%. Exposure increases can be expected in patients with renal impairment. Use caution when administering phentermine to patients with renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="bfa51089-b121-48e7-82dc-37a832a214b3">
               <id root="555aeaff-4295-49d7-91ee-cb4d7919c383"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">CLINICAL STUDIES</content>
               </title>
               <text>
                  <paragraph>In relatively short-term clinical trials, adult obese subjects instructed in dietary management and treated with “anorectic” drugs lost more weight on the average than those treated with placebo and diet.</paragraph>
                  <paragraph>The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased weight loss due to the various drug effects are not established. The amount of weight loss associated with the use of an “anorectic” drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drugs prescribed, such as the physician-investigator, the population treated and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.</paragraph>
                  <paragraph>The natural history of obesity is measured over several years, whereas the studies cited are restricted to a few weeks’ duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.</paragraph>
               </text>
               <effectiveTime value="20160822"/>
            </section>
         </component>
         <component>
            <section ID="L79784bcf-791f-443e-98fa-2ffd423331d3">
               <id root="6c6c3ff6-7528-4578-b4a3-dd650020f92a"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>LOMAIRA™ tablets are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity in patients with an initial body mass index greater than or equal to 30 kg/m
 
  <sup>2</sup>, or greater than or equal to 27 kg/m
 
  <sup>2</sup>in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).

 </paragraph>
                  <paragraph>Below is a chart of body mass index (BMI) based on various heights and weights.</paragraph>
                  <paragraph>BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches x 0.0254 = meters.</paragraph>
                  <paragraph>BODY MASS INDEX (BMI), kg/m
 
  <sup>2</sup>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lc1e8677a-4e8c-4d95-ad5d-84345468c98d"/>
                  </paragraph>
                  <paragraph>The limited usefulness of agents of this class, including phentermine (see
 
  <content styleCode="italics">
                        <linkHtml href="#b60fdbe9-14c5-4f42-8550-24170e2d8000">Clinical Pharmacology</linkHtml>
                     </content>), should be measured against possible risk factors inherent in their use such as those described below.

 </paragraph>
               </text>
               <effectiveTime value="20181218"/>
               <component>
                  <observationMedia ID="Lc1e8677a-4e8c-4d95-ad5d-84345468c98d">
                     <text>table</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="table-figure-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L6b95dbaf-d2f1-4ac0-94d3-32c00ce213ba">
               <id root="30bfaf29-53a0-44bc-a9dd-4d7e074cec3f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>• History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) 
  <br/>  • During or within 14 days following the administration of monoamine oxidase inhibitors 
  <br/>  • Hyperthyroidism 
  <br/>  • Glaucoma 
  <br/>  • Agitated states 
  <br/>  • History of drug abuse 
  <br/>  • Pregnancy (see
 
  <content styleCode="italics">
                        <linkHtml href="#Lf4c0d695-89b0-46f5-a9e7-2bb5c7990252">Precautions</linkHtml>
                     </content>) 
  <br/>  • Nursing (see
 
  <content styleCode="italics">
                        <linkHtml href="#Lf4c0d695-89b0-46f5-a9e7-2bb5c7990252">Precautions</linkHtml>
                     </content>) 
  <br/>  • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines

 </paragraph>
               </text>
               <effectiveTime value="20160823"/>
            </section>
         </component>
         <component>
            <section ID="Lc182a125-976d-4cdc-baaf-3853be940359">
               <id root="d17bc620-7b33-4f4c-abc9-1d13c0856d75"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>
                  <content styleCode="bold">WARNINGS</content>
               </title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20160823"/>
               <component>
                  <section ID="L06515fbe-c813-44c4-9359-273cd564c789">
                     <id root="5c85f108-13f7-4efd-8d4c-0c5753f76fe5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Coadministration with Other Drug Products for Weight Loss</content>
                     </title>
                     <text>
                        <paragraph>LOMAIRA™ tablets are indicated only as short-term (a few weeks) monotherapy for the management of exogenous obesity. The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of phentermine and these drug products is not recommended.</paragraph>
                     </text>
                     <effectiveTime value="20160823"/>
                  </section>
               </component>
               <component>
                  <section ID="L6ade5107-532c-4ed8-aa1d-5af2c2fdd6ed">
                     <id root="9070ba0d-74a8-467e-9f02-6f84a80ffc20"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Primary Pulmonary Hypertension</content>
                     </title>
                     <text>
                        <paragraph>Primary Pulmonary Hypertension (PPH) – a rare, frequently fatal disease of the lungs – has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone. The initial symptom of PPH is usually dyspnea. Other initial symptoms may include angina pectoris, syncope or lower extremity edema. Patients should be advised to report immediately any deterioration in exercise tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema, and patients should be evaluated for the possible presence of pulmonary hypertension.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="L3e2be815-3146-46dc-8b5b-7f4cc5b956e7">
                     <id root="9506e5a4-b93b-4160-ab7a-dd5dbc37284b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Valvular Heart Disease</content>
                     </title>
                     <text>
                        <paragraph>Serious regurgitant cardiac valvular disease, primarily affecting the mitral, aortic and/or tricuspid valves, has been reported in otherwise healthy persons who had taken a combination of phentermine with fenfluramine or dexfenfluramine for weight loss. The possible role of phentermine in the etiology of these valvulopathies has not been established and their course in individuals after the drugs are stopped is not known. The possibility of an association between valvular heart disease and the use of phentermine alone cannot be ruled out; there have been rare cases of valvular heart disease in patients who reportedly have taken phentermine alone.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="Lf84660ed-6bd6-4fdc-802b-e9df607918a1">
                     <id root="ba1638ca-0ddc-4deb-99cb-256dd520dcb3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Development of Tolerance, Discontinuation in Case of Tolerance</content>
                     </title>
                     <text>
                        <paragraph>When tolerance to the anorectant effect develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="Le9fb2b45-f3ff-4aca-8fe3-8a67d50e11ab">
                     <id root="4f5fead1-5776-430b-856d-7a29fca94e74"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Effect on the Ability to Engage in Potentially Hazardous Tasks</content>
                     </title>
                     <text>
                        <paragraph>Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="Lbe22d0d8-9689-4a5d-b1fc-62e0f9d4d17a">
                     <id root="3ea78429-67a6-44a5-a5f9-c4144e1bd73d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Risk of Abuse and Dependence</content>
                     </title>
                     <text>
                        <paragraph>Phentermine is related chemically and pharmacologically to amphetamine (d- and dll-amphetamine) and other related stimulant drugs have been extensively abused. The possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. See
 
  <content styleCode="italics">
                              <linkHtml href="#L1c5678a8-ba5f-4fe8-937c-d7bca5a0daf6">Adverse Reactions</linkHtml>/
  
   <linkHtml href="#Ld027bf04-7ae4-43d5-83ea-807668ba8f7b">Drug Abuse and Dependence</linkHtml>
                           </content>and
 
  <content styleCode="italics">
                              <linkHtml href="#L76c674e3-ce0b-4006-ae5c-9ff7a73f9743">Overdosage</linkHtml>
                           </content>.

 </paragraph>
                        <paragraph>The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.</paragraph>
                     </text>
                     <effectiveTime value="20160823"/>
                  </section>
               </component>
               <component>
                  <section ID="Lef7f0b8b-3303-4810-aa93-6c17bd75d9d8">
                     <id root="4719f21a-0d2b-4c28-867d-f265d5a69ae1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Usage with Alcohol</content>
                     </title>
                     <text>
                        <paragraph>Concomitant use of alcohol with phentermine may result in an adverse drug reaction.</paragraph>
                     </text>
                     <effectiveTime value="20160823"/>
                  </section>
               </component>
               <component>
                  <section ID="Laa3a05df-b6b4-4177-89df-c8b805bf594d">
                     <id root="01509149-1bbf-4acc-b382-8642c42f3c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Use in Patients with Hypertension</content>
                     </title>
                     <text>
                        <paragraph>Use caution in prescribing phentermine for patients with even mild hypertension (risk of increase in blood pressure).</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="L2f179c3f-f4dc-4d18-970d-f9c40f1e3210">
                     <id root="5c43cdec-9bb7-465c-a78f-ba1989a43def"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Use in Patients on Insulin or Oral Hypoglycemic Medications for Diabetes Mellitus</content>
                     </title>
                     <text>
                        <paragraph>A reduction in insulin or oral hypoglycemic medications in patients with diabetes mellitus may be required.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lf4c0d695-89b0-46f5-a9e7-2bb5c7990252">
               <id root="01c7909d-f9b2-4ad3-b09d-b9c277d10eb6"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">PRECAUTIONS</content>
               </title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20160916"/>
               <component>
                  <section ID="L880a61e7-c8dd-485f-9a4e-628c6c226683">
                     <id root="00b13429-aa18-409f-9c8d-7e8ecb74bf47"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Information for Patients</content>
                     </title>
                     <text>
                        <paragraph>Patients must be informed that phentermine hydrochloride is a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity, and that coadministration of phentermine with other drugs for weight loss is not recommended (see 
 
  <content styleCode="italics">
                              <linkHtml href="#L79784bcf-791f-443e-98fa-2ffd423331d3">Indications and Usage</linkHtml>
                           </content>and
 
  <content styleCode="italics">
                              <linkHtml href="#Lc182a125-976d-4cdc-baaf-3853be940359">Warnings</linkHtml>
                           </content>).

 </paragraph>
                        <paragraph>Patients must be instructed on how much phentermine to take, and when and how to take it (see
 
  <content styleCode="italics">
                              <linkHtml href="#L877314f1-a061-4a8b-917e-e4d6cf0aa2d4">Dosage and Administration</linkHtml>
                           </content>).

 </paragraph>
                        <paragraph>Advise pregnant women and nursing mothers not to use phentermine (see 
 
  <content styleCode="italics">
                              <linkHtml href="#Lf4c0d695-89b0-46f5-a9e7-2bb5c7990252">Precautions</linkHtml>
                           </content>).

 </paragraph>
                        <paragraph>Patients must be informed about the risks of use of phentermine (including the risks discussed in
 
  <content styleCode="italics">
                              <linkHtml href="#Lc182a125-976d-4cdc-baaf-3853be940359">Warnings</linkHtml>
                           </content>and
 
  <content styleCode="italics">
                              <linkHtml href="#Lf4c0d695-89b0-46f5-a9e7-2bb5c7990252">Precautions</linkHtml>
                           </content>), about the symptoms of potential adverse reactions and when to contact a physician and/or take other action. The risks include, but are not limited to:

 </paragraph>
                        <paragraph>• Development of primary pulmonary hypertension (see 
 
  <content styleCode="italics">
                              <linkHtml href="#Lc182a125-976d-4cdc-baaf-3853be940359">Warnings</linkHtml>
                           </content>) 
  <br/>  • Development of serious valvular heart disease (see
 
  <content styleCode="italics">
                              <linkHtml href="#Lc182a125-976d-4cdc-baaf-3853be940359">Warnings</linkHtml>
                           </content>) 
  <br/>  • Effects on the ability to engage in potentially hazardous tasks (see 
 
  <content styleCode="italics">
                              <linkHtml href="#Lc182a125-976d-4cdc-baaf-3853be940359">Warnings</linkHtml>
                           </content>) 
  <br/>  • The risk of an increase in blood pressure (see
 
  <content styleCode="italics">
                              <linkHtml href="#Lc182a125-976d-4cdc-baaf-3853be940359">Warnings</linkHtml>
                           </content>and
 
  <content styleCode="italics">
                              <linkHtml href="#L1c5678a8-ba5f-4fe8-937c-d7bca5a0daf6">Adverse Reactions</linkHtml>
                           </content>) 
  <br/>  • The risk of interactions (see
 
  <content styleCode="italics">
                              <linkHtml href="#L6b95dbaf-d2f1-4ac0-94d3-32c00ce213ba">Contraindications</linkHtml>
                           </content>,
 
  <content styleCode="italics">
                              <linkHtml href="#Lc182a125-976d-4cdc-baaf-3853be940359">Warnings</linkHtml>
                           </content>, and
 
  <content styleCode="italics">
                              <linkHtml href="#Lf4c0d695-89b0-46f5-a9e7-2bb5c7990252">Precautions</linkHtml>/
  
   <linkHtml href="#L9fef2f0a-6478-4965-844b-d40485f2a75a">Drug Interactions</linkHtml>
                           </content>)

 </paragraph>
                        <paragraph>The patients must also be informed about</paragraph>
                        <paragraph>• the potential for developing tolerance and actions if they suspect development of tolerance (see
 
  <content styleCode="italics">
                              <linkHtml href="#Lc182a125-976d-4cdc-baaf-3853be940359">Warnings</linkHtml>
                           </content>) and 
  <br/>  • the risk of dependence and the potential consequences of abuse (see
 
  <content styleCode="italics">
                              <linkHtml href="#Lc182a125-976d-4cdc-baaf-3853be940359">Warnings</linkHtml>
                           </content>,
 
  <content styleCode="italics">
                              <linkHtml href="#Ld027bf04-7ae4-43d5-83ea-807668ba8f7b">Drug Abuse and Dependence</linkHtml>
                           </content>, and
 
  <content styleCode="italics">
                              <linkHtml href="#L76c674e3-ce0b-4006-ae5c-9ff7a73f9743">Overdosage</linkHtml>
                           </content>).

 </paragraph>
                        <paragraph>Tell patients to keep phentermine in a safe place to prevent theft, accidental overdose, misuse or abuse. Selling or giving away phentermine may harm others and is against the law.</paragraph>
                     </text>
                     <effectiveTime value="20160916"/>
                  </section>
               </component>
               <component>
                  <section ID="L9fef2f0a-6478-4965-844b-d40485f2a75a">
                     <id root="bbc2ebee-3a65-4df5-8b60-4147f59b7a47"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Drug Interactions</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Monoamine Oxidase Inhibitors</content>
                        </paragraph>
                        <paragraph>Use of phentermine is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors because of the risk of hypertensive crisis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Alcohol</content>
                        </paragraph>
                        <paragraph>Concomitant use of alcohol with phentermine may result in an adverse drug reaction.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Insulin and Oral Hypoglycemic Medications</content>
                        </paragraph>
                        <paragraph>Requirements may be altered (see
 
  <content styleCode="italics">
                              <linkHtml href="#Lc182a125-976d-4cdc-baaf-3853be940359">Warnings</linkHtml>
                           </content>)

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Adrenergic Neuron Blocking Drugs</content>
                        </paragraph>
                        <paragraph>Phentermine may decrease the hypotensive effect of adrenergic neuron blocking drugs.</paragraph>
                     </text>
                     <effectiveTime value="20160823"/>
                  </section>
               </component>
               <component>
                  <section ID="L09fee0d1-d0c6-4b62-a590-1a14d83d3b3e">
                     <id root="2a6b2a19-3fbd-4453-90b7-5998ed774ccf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>Studies have not been performed with phentermine to determine the potential for carcinogenesis, mutagenesis or impairment of fertility.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="L6c9b1121-0896-44b8-84b2-33c17ad8d341">
                     <id root="8dfc24b0-2758-44fd-b17a-75f03030da97"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Pregnancy Category X</content>
                        </paragraph>
                        <paragraph>Phentermine is contraindicated during pregnancy because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm. A minimum weight gain, and no weight loss, is currently recommended for all pregnant women, including those who are already overweight or obese, due to obligatory weight gain that occurs in maternal tissues during pregnancy. Phentermine has pharmacologic activity similar to amphetamine (d- and dll-amphetamine) (see
 
  <content styleCode="italics">
                              <linkHtml href="#b60fdbe9-14c5-4f42-8550-24170e2d8000">Clinical Pharmacology</linkHtml>
                           </content>). Animal reproduction studies have not been conducted with phentermine. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

 </paragraph>
                     </text>
                     <effectiveTime value="20160823"/>
                  </section>
               </component>
               <component>
                  <section ID="Leaecf4ba-d484-4580-b683-979bce1f077c">
                     <id root="8b01bb72-47e8-4d71-a6f1-38c8aa8be92f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Nursing Mothers</content>
                     </title>
                     <text>
                        <paragraph>It is not known if phentermine is excreted in human milk; however, other amphetamines are present in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="L84977d68-8054-44c4-b989-752a0220dbbb">
                     <id root="f512758e-2371-4c3c-885d-328fbdaba42c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established. Because pediatric obesity is a chronic condition requiring long-term treatment, the use of this product, approved for short-term therapy, is not recommended.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="Lf49d9817-be16-401b-90af-033aabd7f6c5">
                     <id root="8293ae49-8435-408a-94a7-e7a68a09a3f7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="Lbbad8b28-8e3e-4931-9abd-b9ff31cd92c0">
                     <id root="9e678b56-c0cd-450f-9001-d6862f11b9f5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Renal Impairment</content>
                     </title>
                     <text>
                        <paragraph>Phentermine was not studied in patients with renal impairment. Based on the reported excretion of phentermine in urine, exposure increases can be expected in patients with renal impairment. Use caution when administering phentermine to patients with renal impairment (see
 
  <content styleCode="italics">
                              <linkHtml href="#b60fdbe9-14c5-4f42-8550-24170e2d8000">Clinical Pharmacology</linkHtml>
                           </content>).

 </paragraph>
                     </text>
                     <effectiveTime value="20160823"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L1c5678a8-ba5f-4fe8-937c-d7bca5a0daf6">
               <id root="41d3c197-eaf6-4afa-9d9f-06d6e7a78b9f"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following adverse reactions are described, or described in greater detail, in other sections:</paragraph>
                  <paragraph>- Primary pulmonary hypertension (see
 
  <content styleCode="italics">
                        <linkHtml href="#Lc182a125-976d-4cdc-baaf-3853be940359">Warnings</linkHtml>
                     </content>)

 </paragraph>
                  <paragraph>- Valvular heart disease (see
 
  <content styleCode="italics">
                        <linkHtml href="#Lc182a125-976d-4cdc-baaf-3853be940359">Warnings</linkHtml>
                     </content>)

 </paragraph>
                  <paragraph>- Effect on the ability to engage in potentially hazardous tasks (see
 
  <content styleCode="italics">
                        <linkHtml href="#Lc182a125-976d-4cdc-baaf-3853be940359">Warnings</linkHtml>
                     </content>)

 </paragraph>
                  <paragraph>- Withdrawal effects following prolonged high dosage administration (see
 
  <content styleCode="italics">
                        <linkHtml href="#Ld027bf04-7ae4-43d5-83ea-807668ba8f7b">Drug Abuse and</linkHtml>
                     </content>
                     <br/>
                     <content styleCode="italics">
                        <linkHtml href="#Ld027bf04-7ae4-43d5-83ea-807668ba8f7b">Dependence</linkHtml>
                     </content>)

 </paragraph>
                  <paragraph>The following adverse reactions to phentermine have been identified:</paragraph>
               </text>
               <effectiveTime value="20160916"/>
               <component>
                  <section ID="L33781fae-c448-491f-ae59-13e69b64ebef">
                     <id root="10a0950c-741f-4a7b-b783-f8685434b349"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Cardiovascular</content>
                     </title>
                     <text>
                        <paragraph>Primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevation of blood pressure, ischemic events.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="Lce37010e-0cd3-411e-879f-cd0b9cc197d7">
                     <id root="3c0255cc-5155-4721-98ec-59ac4785877a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Central Nervous System</content>
                     </title>
                     <text>
                        <paragraph>﻿Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, psychosis.﻿</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="L290ecd1f-4dd4-43d4-a7e8-21c225c16c95">
                     <id root="1b81afaa-c2e2-4c62-b09c-d1679b806c48"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Gastrointestinal</content>
                     </title>
                     <text>
                        <paragraph>Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="L8f9940cd-42a9-4761-898f-685b02209f2c">
                     <id root="472c812d-d293-43d5-9bc1-26ce4788ee72"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Allergic</content>
                     </title>
                     <text>
                        <paragraph>Urticaria.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="L1167158c-c9ab-4dab-81ce-82c05e63f99c">
                     <id root="62bdd0d6-8d48-449d-9786-d876cb232106"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Endocrine</content>
                     </title>
                     <text>
                        <paragraph>Impotence, changes in libido.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Ld027bf04-7ae4-43d5-83ea-807668ba8f7b">
               <id root="9214dfee-006d-4417-8c99-58657ed4ff07"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>
                  <content styleCode="bold">DRUG ABUSE AND DEPENDENCE</content>
               </title>
               <text/>
               <effectiveTime value="20160822"/>
               <component>
                  <section ID="La6c1cbed-95e1-400c-a33d-a7b488bb671c">
                     <id root="7052144d-610e-430e-b299-482c36d06537"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Controlled Substance</content>
                     </title>
                     <text>
                        <paragraph>Phentermine is a Schedule IV controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="L8d72b9c4-b5d2-4e7d-901a-d264bf5689f9">
                     <id root="585b8baa-ad4c-49b6-8dd4-5762cd8eb103"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Abuse</content>
                     </title>
                     <text>
                        <paragraph>Phentermine is related chemically and pharmacologically to the amphetamines. Amphetamines and other stimulant drugs have been extensively abused and the possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
               <component>
                  <section ID="L7b3011f0-5268-42c9-ba10-67ed055cadbe">
                     <id root="6d6aadf2-7d44-4aa9-a2fa-e67fb6396bd3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Dependence</content>
                     </title>
                     <text>
                        <paragraph>Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage of these drugs to many times than recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. A severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.</paragraph>
                     </text>
                     <effectiveTime value="20160822"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L76c674e3-ce0b-4006-ae5c-9ff7a73f9743">
               <id root="8afbb762-2fa0-4a27-95a3-92896d3d34a5"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.</paragraph>
               </text>
               <effectiveTime value="20160916"/>
               <component>
                  <section ID="L7ae1f43e-ea60-4667-afb1-0d977039ce9f">
                     <id root="70216b68-3c5e-471a-ba36-125f1c1b0766"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Acute Overdosage</content>
                     </title>
                     <text>
                        <paragraph>Manifestations of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmia, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Overdosage of pharmacologically similar compounds has resulted in fatal poisoning usually terminates in convulsions and coma.</paragraph>
                        <paragraph>Management of acute phentermine hydrochloride intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (Regitine
 
  <sup>®</sup>, CIBA) has been suggested on pharmacologic grounds for possible acute, severe hypertension, if this complicates overdosage.

 </paragraph>
                     </text>
                     <effectiveTime value="20160916"/>
                  </section>
               </component>
               <component>
                  <section ID="Laf43460c-6d2c-4bbb-9bec-00bf611a715f">
                     <id root="96c09198-f553-465a-86a9-ee26e55bff67"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">Chronic Intoxication</content>
                     </title>
                     <text>
                        <paragraph>Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia. See
 
  <content styleCode="italics">
                              <linkHtml href="#Ld027bf04-7ae4-43d5-83ea-807668ba8f7b">Drug Abuse and Dependence</linkHtml>
                           </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20160823"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L877314f1-a061-4a8b-917e-e4d6cf0aa2d4">
               <id root="fd467d09-78a0-43a7-ae82-ebde6f268ec8"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Dosage should be individualized to obtain an adequate response with the lowest effective dose. 
  <br/>  The usual adult dose is one tablet three times a day ½ hour before meals. This tablet is scored to facilitate administering one half of the usual dosage for patients not requiring the full dose. Phentermine hydrochloride is not recommended for use in pediatric patients less than or equal to 16 years of age.
 </paragraph>
                  <paragraph>Late evening medication should be avoided because of the possibility of resulting insomnia.</paragraph>
               </text>
               <effectiveTime value="20160822"/>
            </section>
         </component>
         <component>
            <section ID="b0de3de0-4604-4adf-83e4-73d77c5ccaed">
               <id root="7bdfbb5c-f964-419a-866c-ea7443723ce9"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>Product:    50090-7560</paragraph>
                  <paragraph>NDC:    50090-7560-0   90 TABLET in a BOTTLE</paragraph>
               </text>
               <effectiveTime value="20250528"/>
            </section>
         </component>
         <component>
            <section>
               <id root="3b3c6a1e-7bd2-478f-bcf5-2f257e665ebe"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Phentermine Hydrochloride</title>
               <text>
                  <renderMultiMedia referencedObject="lbl500907560"/>
               </text>
               <effectiveTime value="20250528"/>
               <component>
                  <observationMedia ID="lbl500907560">
                     <text>Label Image</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="lbl500907560.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>